Evaluation of miR-145, connective tissue growth factor(CTGF) and CX3CL1 in SLE patients.
Not Applicable
- Conditions
- Health Condition 1: M321- Systemic lupus erythematosus withorgan or system involvement
- Registration Number
- CTRI/2023/10/058879
- Lead Sponsor
- All India Institute of Medical Sciences Raipur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients of SLE fulfilling EULAR/ACR criteria.
2. SLE patients either newly diagnosed, or previously diagnosed but not on treatment except prednisolone <10 mg/day or equivalent dose dose of another corticosteroid.
Exclusion Criteria
1. Pregnant and lactating females
2. dose of prednisolone > 10 mg/day or, equivalent dose of another corticosteroid.
3. Patients who received any immunosuppressive medicines in last 6 months
4. Malignancy
5. Patients with chronic hepatitis B,C, or HIV
6. Patients with chronic liver disease or chronic kidney disease
7. Any active infection
8. Presence of diabetic mellitus
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Independent variables- age & gender, SLEDAI score <br/ ><br>Outcome variables- Level of miRNA, CTGF & fractalkine. <br/ ><br> <br/ ><br>Identification of these biomarkers with disease severity can uphold them as non-invasive markers for organ damage and assessment of disease activity. They can serve as predictors of disease progression. Theymight also provide them as potential candidates for the treatment of SLE. <br/ ><br>Timepoint: 0 <br/ ><br>3 month <br/ ><br>6 month <br/ ><br>
- Secondary Outcome Measures
Name Time Method Independent variables - ANA, ANA blot <br/ ><br> <br/ ><br>Outcome variables - miR-145, CTGF & FractalkineTimepoint: 0 <br/ ><br>3 month <br/ ><br>6 month